MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis

Michael D. Morgan; Nashwa Al-Shaarawy; Steve Martin; James I. Robinson; Sarah Twigg; YEAR Consortium; Awadalla A. Magdy; Aziza Sayed Omar; Maivel H. Ghattas; Paul Emery; Jennifer H. Barrett; Ann W. Morgan

doi:10.2217/pgs.13.235

MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis

Michael D. Morgan, Nashwa Al-Shaarawy, Steve Martin, James I. Robinson, Sarah Twigg, YEAR Consortium, Awadalla A. Magdy, Aziza Sayed Omar, Maivel H. Ghattas, Paul Emery, Jennifer H. Barrett, Ann W. Morgan^* (Corresponding Author)

^*Corresponding author for this work

Medical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: To date, functional MTHFR SNPs have been tested for their impact on low-dose methotrexate (MTX) response in small rheumatoid arthritis (RA) cohorts. We sought to test their effect in the single largest cohort studied to date, and undertook a meta-analysis utilizing stringent study inclusion criteria.

Materials & methods: RA patients treated with MTX monotherapy from the Yorkshire Early Arthritis Register (YEAR) were genotyped using RFLP assays, and tested for association with treatment efficacy. Studies for meta-analysis were screened by a set of stringent inclusion criteria.

Results & conclusion: rs1801131 and rs1801133 were not associated with response to MTX in the YEAR cohort, nor did they affect the probability of achieving a low disease activity state. A meta-analysis of comparable studies found no association with these SNPs. MTHFR SNPs rs1801131 and rs1801133 are unlikely to have a clinically meaningful effect on the first 6 months of MTX treatment in early RA.

Original language	English
Journal	Pharmacogenomics
Volume	15
Issue number	4
DOIs	https://doi.org/10.2217/pgs.13.235
Publication status	Published - 2014

Access to Document

10.2217/pgs.13.235

Cite this

@article{ead679ec9a4843e08d685d2311ca5731,

title = "MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis",

abstract = "Aim: To date, functional MTHFR SNPs have been tested for their impact on low-dose methotrexate (MTX) response in small rheumatoid arthritis (RA) cohorts. We sought to test their effect in the single largest cohort studied to date, and undertook a meta-analysis utilizing stringent study inclusion criteria. Materials & methods: RA patients treated with MTX monotherapy from the Yorkshire Early Arthritis Register (YEAR) were genotyped using RFLP assays, and tested for association with treatment efficacy. Studies for meta-analysis were screened by a set of stringent inclusion criteria. Results & conclusion: rs1801131 and rs1801133 were not associated with response to MTX in the YEAR cohort, nor did they affect the probability of achieving a low disease activity state. A meta-analysis of comparable studies found no association with these SNPs. MTHFR SNPs rs1801131 and rs1801133 are unlikely to have a clinically meaningful effect on the first 6 months of MTX treatment in early RA.",

author = "Morgan, {Michael D.} and Nashwa Al-Shaarawy and Steve Martin and Robinson, {James I.} and Sarah Twigg and YEAR Consortium and Magdy, {Awadalla A.} and Omar, {Aziza Sayed} and Ghattas, {Maivel H.} and Paul Emery and Barrett, {Jennifer H.} and Morgan, {Ann W.}",

year = "2014",

doi = "10.2217/pgs.13.235",

language = "English",

volume = "15",

journal = "Pharmacogenomics",

issn = "1744-8042",

publisher = "Future Science",

number = "4",

}

TY - JOUR

T1 - MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis

AU - Morgan, Michael D.

AU - Al-Shaarawy, Nashwa

AU - Martin, Steve

AU - Robinson, James I.

AU - Twigg, Sarah

AU - Consortium, YEAR

AU - Magdy, Awadalla A.

AU - Omar, Aziza Sayed

AU - Ghattas, Maivel H.

AU - Emery, Paul

AU - Barrett, Jennifer H.

AU - Morgan, Ann W.

PY - 2014

Y1 - 2014

N2 - Aim: To date, functional MTHFR SNPs have been tested for their impact on low-dose methotrexate (MTX) response in small rheumatoid arthritis (RA) cohorts. We sought to test their effect in the single largest cohort studied to date, and undertook a meta-analysis utilizing stringent study inclusion criteria. Materials & methods: RA patients treated with MTX monotherapy from the Yorkshire Early Arthritis Register (YEAR) were genotyped using RFLP assays, and tested for association with treatment efficacy. Studies for meta-analysis were screened by a set of stringent inclusion criteria. Results & conclusion: rs1801131 and rs1801133 were not associated with response to MTX in the YEAR cohort, nor did they affect the probability of achieving a low disease activity state. A meta-analysis of comparable studies found no association with these SNPs. MTHFR SNPs rs1801131 and rs1801133 are unlikely to have a clinically meaningful effect on the first 6 months of MTX treatment in early RA.

AB - Aim: To date, functional MTHFR SNPs have been tested for their impact on low-dose methotrexate (MTX) response in small rheumatoid arthritis (RA) cohorts. We sought to test their effect in the single largest cohort studied to date, and undertook a meta-analysis utilizing stringent study inclusion criteria. Materials & methods: RA patients treated with MTX monotherapy from the Yorkshire Early Arthritis Register (YEAR) were genotyped using RFLP assays, and tested for association with treatment efficacy. Studies for meta-analysis were screened by a set of stringent inclusion criteria. Results & conclusion: rs1801131 and rs1801133 were not associated with response to MTX in the YEAR cohort, nor did they affect the probability of achieving a low disease activity state. A meta-analysis of comparable studies found no association with these SNPs. MTHFR SNPs rs1801131 and rs1801133 are unlikely to have a clinically meaningful effect on the first 6 months of MTX treatment in early RA.

U2 - 10.2217/pgs.13.235

DO - 10.2217/pgs.13.235

M3 - Article

SN - 1744-8042

VL - 15

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 4

ER -

MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis

Abstract

Access to Document

Fingerprint

Cite this